Orange Book product · Generic (ANDA)
GABAPENTIN
GABAPENTIN
At a glance
Feb 26, 2024
Approved
Generic (ANDA)
Application
AB2
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 26, 2024
2 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
GABAPENTIN
Strength
300MG
Dosage form
TABLET
Route
ORAL
TE code
AB2
Application
ANDA 218075
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of GABAPENTIN
- 2000NEURONTINBrand (NDA)
NDA 021129 · VIATRIS
- 1993NEURONTINBrand (NDA)
NDA 020235 · VIATRIS
- 2026GABAPENTINGeneric (ANDA)
ANDA 219814 · PRINSTON INC
- 2025GABAPENTINGeneric (ANDA)
ANDA 219319 · SENORES PHARMS
- 2024GABAPENTINGeneric (ANDA)
ANDA 203643 · ABON PHARMS LLC
- 2024GABAPENTINGeneric (ANDA)
ANDA 216252 · EPIC PHARMA LLC
- 2024GABAPENTINGeneric (ANDA)
ANDA 217682 · ANNORA PHARMA
- 2023GABAPENTINGeneric (ANDA)
ANDA 208928 · IPCA LABS LTD
- 2023GABAPENTINGeneric (ANDA)
ANDA 217546 · LAURUS
- 2023GABAPENTINGeneric (ANDA)
ANDA 217116 · GRANULES
- 2023GABAPENTINGeneric (ANDA)
ANDA 216492 · RUBICON RESEARCH
- 2021GABAPENTINGeneric (ANDA)
ANDA 214957 · ASCENT PHARMS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
